Home/Pipeline/DCR-MYC

DCR-MYC

Hepatocellular Carcinoma

PreclinicalDiscontinued

Key Facts

Indication

Hepatocellular Carcinoma

Phase

Preclinical

Status

Discontinued

Company

Dicerna Pharmaceuticals

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals established itself as a leader in next-generation RNAi therapeutics through its proprietary, liver-targeted GalXC™ and GalXC-Plus™ technology platforms. The company advanced a promising pipeline, most notably nedosiran for primary hyperoxaluria, and forged significant partnerships with industry leaders like Novo Nordisk, Roche, and Eli Lilly. Its successful trajectory culminated in a strategic acquisition by Novo Nordisk in December 2021, integrating Dicerna's platform to expand the acquirer's capabilities in genetic medicine for cardiometabolic and rare diseases.

View full company profile

Therapeutic Areas

Rare Diseases Cardiometabolic Liver Diseases

Other Hepatocellular Carcinoma Drugs

Drug	Company	Phase	Status
Namodenoson (CF102)	Can Fite Biopharma	Phase IIb/III	Active
RYZ801	RayzeBio	Preclinical	Active
RG6139 (RO7247669)	Chugai Pharmaceutical	Phase III	Active
ALN-BCAT	Alnylam Pharmaceuticals	Phase 1	Active
HCC Program	Arcellx	Discovery	Active
TTFields	Novocure	Pilot	Active
RP2	Replimune	Phase 2	Active, Enrolling
188RNL-BAM	Plus Therapeutics	Preclinical	In Development
Temferon	Genenta Science	Preclinical	Investigational